Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 35

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 35
---
 from even greater control by Broadwood Lengthy and significant disruption to patients, surgeons, employees, distributors, partners and stockholders Vote Against Vote For Certain and immediate cash value Significant premium by any measure Attractive valuation multiple De-risks standalone plan and addresses headwinds Accelerates ICL adoption by more surgeons for the benefit of more patients worldwide Unanimously recommended and approved by STAAR’s independent and experienced Board O P $28.00 per share all-cash offer $18.49 per share prior to announcement If the Alcon merger agreement is terminated, it could be a deterrent to any future buyers. Not only is there a risk of damage to potential future sale processes, but there is no guarantee that Alcon would participate in any future process. Alcon is paying STAAR stockholders a 59% premium to the 90-day VWAP. Broadwood’s proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR’s Board Unanimously Believes the Alcon Merger Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders. STAAR Stockholders are Encouraged to Reject the Flawed and Misleading Claims of Broadwood Partners and Vote “FOR” the Alcon Merger on the WHITE Proxy Card.

Exhibit 99.2

STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved

Proposed Merger Represents a Compelling 59% Premium to the 90-DayVWAP Prior to Announcement

STAAR’s Business Risks and Challenges are Increasing and Competition is Intensifying

China Net Sales, which Represent Approximately Half of STAAR’s Consolidated Net Sales, Have Declined Since 2023, and Procedure Volumes Remain Weak

Broadwood Partners’ Claims Against the Merger are Flawed and Misleading and Reflect a Misunderstanding of STAAR’s Standalone Challenges, Value, and Potential Buyer Interest in STAAR

STAAR’s Stock Traded at $18.49 per Share Prior to Announcement – If the Merger is not Approved, STAAR Expects its Valuation Would Face Considerable Downward Pressure, Especially in